» Articles » PMID: 23773925

B-cell Activating Factor (BAFF) is Elevated in Chronic Granulomatous Disease

Abstract

Chronic Granulomatous Disease (CGD) is an inherited defect in superoxide production leading to life-threatening infections, granulomas, and, possibly, abnormal immunoglobulin concentrations. We investigated whether factors controlling antibody production, such as B-cell activating factor (BAFF), were altered in CGD. CGD subjects had significantly increased mean (2.3-fold, p < 0.0001) plasma concentrations of BAFF compared to healthy donors. Patients on IFN-γ treatment had significantly higher BAFF concentrations compared with CGD patients not taking IFN-γ (1.6-fold, p < 0.005). Leukocytes from CGD subjects produced normal amounts of BAFF in response to IFN-γ or G-CSF in vitro. Expression of BAFF-R and TACI was significantly reduced on CGD B cells. Elevated BAFF in CGD correlated with CRP (R = 0.44), ESR (R = 0.49), and IgM (R = 0.47) and increased rapidly in healthy subjects following intravenous endotoxin administration. These findings suggest that elevated BAFF in CGD subjects and healthy donors is a consequence of acute and chronic inflammation.

Citing Articles

Genetically supported causality between gut microbiota, immune cells and morphine tolerance: a two-sample Mendelian randomization study.

Han S, Gao J, Wang Z, Xiao Y, Ge Y, Liang Y Front Microbiol. 2024; 15:1343763.

PMID: 38389539 PMC: 10882271. DOI: 10.3389/fmicb.2024.1343763.


Beyond the Extra Respiration of Phagocytosis: NADPH Oxidase 2 in Adaptive Immunity and Inflammation.

Mortimer P, Mc Intyre S, Thomas D Front Immunol. 2021; 12:733918.

PMID: 34539670 PMC: 8440999. DOI: 10.3389/fimmu.2021.733918.


Hyper-responsive Toll-like receptor 7 and 9 activation in NADPH oxidase-deficient B lymphoblasts.

McLetchie S, Volpp B, Dinauer M, Blum J Immunology. 2015; 146(4):595-606.

PMID: 26340429 PMC: 4693894. DOI: 10.1111/imm.12530.


The strength of the antibody response to the nematode Ascaris lumbricoides inversely correlates with levels of B-Cell Activating Factor (BAFF).

Bornacelly A, Mercado D, Acevedo N, Caraballo L BMC Immunol. 2014; 15:22.

PMID: 24906685 PMC: 4067067. DOI: 10.1186/1471-2172-15-22.

References
1.
Kreuzaler M, Rauch M, Salzer U, Birmelin J, Rizzi M, Grimbacher B . Soluble BAFF levels inversely correlate with peripheral B cell numbers and the expression of BAFF receptors. J Immunol. 2011; 188(1):497-503. DOI: 10.4049/jimmunol.1102321. View

2.
Kuhns D, Alvord W, Heller T, Feld J, Pike K, Marciano B . Residual NADPH oxidase and survival in chronic granulomatous disease. N Engl J Med. 2010; 363(27):2600-10. PMC: 3069846. DOI: 10.1056/NEJMoa1007097. View

3.
de Oliveira-Junior E, Bustamante J, Newburger P, Condino-Neto A . The human NADPH oxidase: primary and secondary defects impairing the respiratory burst function and the microbicidal ability of phagocytes. Scand J Immunol. 2011; 73(5):420-7. DOI: 10.1111/j.1365-3083.2010.02501.x. View

4.
Sutherland A, Ng L, Fletcher C, Shum B, Newton R, Grey S . BAFF augments certain Th1-associated inflammatory responses. J Immunol. 2005; 174(9):5537-44. DOI: 10.4049/jimmunol.174.9.5537. View

5.
Moreaux J, Legouffe E, Jourdan E, Quittet P, Reme T, Lugagne C . BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood. 2004; 103(8):3148-57. PMC: 2387243. DOI: 10.1182/blood-2003-06-1984. View